Efficacy and safety of low-dose tetracycline, amoxicillin quadruple therapy in Helicobacter pylori infection: A retrospective single center study

Table 1 Demographic and clinical data of patients

Variables	500 mg bid (n = 73)	500 mg tid (n = 74)	750 mg bid (n = 71)	P value
Age, mean ± SD	49.2 ± 12.0	50.2 ± 13.9	46.6 ± 15.8	0.348
Age range (years)	20-72	23-72	22-77
Age, ≤ 50 years	36	35	40	0.523
Sex, male/female	41/32	39/35	40/31	0.899
Family history of gastric cancer	1	2	1	1.000
NSAIDS	2	3	0	0.375
Probiotics	7	2	3	0.202
Smoking	15	16	15	1.000
Alcohol drinking	10	14	13	0.689
Hypertension	17	17	15	0.958
Diabetes	5	6	3	0.694
Hyperlipidemia	1	3	1	0.623
Endoscopy diagnosis				0.600
Gastritis	49	42	36
Ulcer	14	7	9
Unknown	10	25	26
Intestinal metaplasia				0.325
No	40	27	22
Yes	23	22	23
Unknown	10	25	26
Treatment times				< 0.001
1	60	42	16
2	8	27	39
≥ 3	5	5	16
Rescue therapy1	13	32	55
PPI				< 0.001
Omeprazole	2	5	27
Rabeprazole	66	63	37
Pantoprazole	1	5	1
Vonoprazan	4	1	6
Bismuth				< 0.001
Bismuth potassium citrate	4	27	37
Colloidal bismuth pectin	69	47	34

¹Rescue therapy was defined as patients who had received eradication therapy once or more but failed.

P values were from two-sided comparisons of the differences between the three groups. 500 mg bid: Tetracycline twice daily; 500 mg tid: Tetracycline three times daily; 750 mg bid: Tetracycline twice daily; NSAIDS: Nonsteroidal anti-inflammatory drugs; PPI: Proton pump inhibitor.